MORGANTOWN, W.Va. – The WVU Rockefeller Neuroscience Institute was first institution in the United States to enroll a patient in the Route 92 Medical, Inc. SUMMIT MAX clinical trial. SUMMIT MAX is a randomized, controlled, multicenter trial to evaluate the performance of its next generation Monopoint™ Reperfusion System versus currently available aspiration catheter technology.
The trial’s first patient was enrolled at Auckland City Hospital in New Zealand, followed shortly by a patient at the WVU Rockefeller Neuroscience Institute.
“We are happy to become the first U.S. site to enroll a patient in the SUMMIT MAX clinical trial evaluating the Monopoint System,” Ansaar Rai, M.D., WVU Rockefeller Neuroscience Institute professor and Neuroradiology Department chair, said. “Randomized clinical trials such as these offer high levels of evidence and are critical in advancing the field of endovascular stroke therapy.”
Read More: https://wvumedicine.org/news/article/wvu-rockefeller-neuroscience-institute-first-in-u-s-to-enroll-patient-in-stroke-clinical-trial_0/